---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-196284"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:36:10.408757+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Homology Medicines cuts ~80 employees, initiates strategic review

## Summary
- Reduction in force of ~80 employees, including CMO Julie Jordan; CCO Michael Blum retained as consultant.
- Estimated restructuring charges of ~$6.8M (severance, benefits) expected in Q3 2023.
- Board begins process to explore strategic options including acquisition, merger, or sale of assets.
- Actions aimed at reducing operating expenses and maximizing shareholder value.

## SEC filing metadata
- accession: 0001193125-23-196284
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312523196284/0001193125-23-196284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312523196284/d510598d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-196284
- JSON: https://secwatch.observer/filing/0001193125-23-196284.json
- Plain text: https://secwatch.observer/filing/0001193125-23-196284.txt

## Key facts
- Restructurings & Charges
  Q32 Bio Inc. announced a restructuring with charges of approximately $6.8 million (approximately 80 employees).
  - Type: restructuring
  - Charge: approximately $6.8 million
  - Headcount: approximately 80 employees
  source text: On July 25, 2023, the Board of Directors (the “ Board ”) of Homology Medicines, Inc. (the “ Company ”) approved a reduction in the Company’s current workforce by approximately 80 employees. The decision was based on cost-reduction initiatives intended to reduce the Company’s ongoing operating expenses and maximize shareholder value as the Company plans to pursue strategic options. The reduction in force included Julie Jordan, M.D., the Company’s Chief Medical Officer and Michael Blum, the Company’s Chief Commercial Officer. The Company intends to retain Mr. Blum as a consultant. The Company currently estimates that it will incur approximately $6.8 million in charges in connection with the reduction in force, primarily consisting of severance payments, employee benefits and related costs, including tax costs and excluding noncash expenses associated with share-based awards.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312523196284/0001193125-23-196284-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.